# US 2024/0199615 A1 · Novel crystalline polymorphs of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199615 A1
- Document ID: US20240199615A1
- Status: Published application
- Kind: A1
- Application number: 17/432,938
- Filed: 2020-02-19
- Published: 2024-06-20
- Earliest claimed: 2019-02-19
- Assignees: Msn Laboratories Private Limited, R&D Center
- Applicants: Msn Laboratories Private Limited, R&D Center
- Inventors: Thirumalai Rajan SRINIVASAN; Eswaraiah SAJJA; Vijayavitthal T MATHAD; Rajeshwar Reddy SAGYAM; Srinivasulu RANGINENI; Venkata Narasayya SALADI
- Web page: https://patentgrep.com/patent/US20240199615A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to novel crystalline polymorphs of 1-[(3R)-3-[4-amino-3(4-phenoxy phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one represented by the following structural formula-1 and process for preparation thereof.

## Claims

### Claim 1

A crystalline form-M1 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 1.

### Claim 2 (depends on 1)

The crystalline form-M1 of compound of formula-1, as per claim 1 having prominent peaks at about 6.8 and 11.6±0.2° of 2θ.

### Claim 3 (depends on 1)

The crystalline form-M1 of compound of formula-1, as per claim 1 is further characterized by having prominent peaks at about 17.6, 18.6, 20.5, 24.5 and 24.8±0.2° of 2θ.

### Claim 4

A process for the preparation of crystalline form-M1 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
a) providing a solution of compound of formula-1 in isopropanol optionally in mixture with a first solvent,
b) optionally filtering the obtained solution,
c) combining the solution with a second solvent at a suitable temperature to provide crystalline form-M1 of compound of formula-1.

### Claim 5 (depends on 4)

The process for preparation as per claim 4, wherein the first solvent is selected from but not limited to polar solvents such as water, polar-aprotic solvents, alcohol solvents, ether solvents or mixtures thereof.

### Claim 6 (depends on 4)

The process for preparation as per claim 4, wherein the second solvent is selected from but not limited to ketone solvents, ester solvents, hydrocarbon solvents, chloro solvents, nitrile solvents or mixtures thereof.

### Claim 7 (depends on 4)

The process for preparation as per claim 4, wherein the first solvent is water.

### Claim 8 (depends on 4)

The process for preparation as per claim 4, wherein the second solvent is n-heptane.

### Claim 9

A crystalline form-M2 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 2.

### Claim 10

A process for preparation of crystalline form-M2 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
a) providing a solution of compound of formula-1 in O-cresol,
b) optionally filtering the obtained solution,
c) combining the solution with a solvent at a suitable temperature to provide crystalline form-M2 of compound of formula-1.

### Claim 11 (depends on 10)

The process for preparation as per claim 10, wherein the solvent is selected from but not limited to ketone solvents, ester solvents, hydrocarbon solvents, chloro solvents, nitrile solvents, ether solvents or mixtures thereof, and the suitable temperature ranges from about −60° C. to about 100° C.

### Claim 12 (depends on 10)

The process for preparation as per claim 10, wherein the solvent is mixture of n-heptane and methyl tertiary butyl ether.

### Claim 13

A crystalline form-M3 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 3.

### Claim 14

A process for preparation of crystalline form-M3 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
a) providing a solution of compound of formula-1 in benzyl alcohol,
b) optionally filtering the obtained solution,
c) combining the solution with a solvent at a suitable temperature to provide crystalline form-M3 of compound of formula-1.

### Claim 15 (depends on 14)

The process for preparation as per claim 14, wherein the solvent is selected from but not limited to ketone solvents, ester solvents, hydrocarbon solvents, chloro solvents, nitrile solvents, ether solvents or mixtures thereof, and the suitable temperature ranges from about −60° C. to about 100° C.

### Claim 16 (depends on 14)

The process for preparation as per claim 14, wherein the solvent is mixture of n-heptane and methyl tertiary butyl ether.

### Claim 17

A crystalline form-M4 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 4.

### Claim 18

A process for preparation of crystalline form-M4 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
a) providing a solution of compound of formula-1 in methyl benzoate,
b) optionally filtering the obtained solution,
c) optionally combining the solution with a solvent at a suitable temperature to provide crystalline form-M4 of compound of formula-1.

### Claim 19 (depends on 18)

The process for preparation as per claim 18, wherein the solvent is selected from but not limited to ketone solvents, ester solvents, hydrocarbon solvents, chloro solvents, nitrile solvents, ether solvents or mixtures thereof, and the suitable temperature ranges from about −60° C. to about 100° C.

### Claim 20 (depends on 18)

The process for preparation as per claim 18, wherein the solvent is n-heptane.

### Claim 21

A crystalline form-M5 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 7.

### Claim 22

The crystalline form-M5 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by peaks at about 6.3, 10.0, 12.8, 13.7, 17.2, 18.1, 19.4, 20.2, 20.9, 21.6, 23.1, 23.7, 24.6, 26.2 and 27.7±0.2° of 2θ.

### Claim 23

A process for the preparation of crystalline form-M5 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
a) suspending compound of formula-1 and methyl paraben in a solvent,
b) isolating crystalline form-M5 of compound of formula-1, and
c) optionally slurrying the material in water.

### Claim 24 (depends on 23)

The process for preparation as per claim 23, wherein the solvent is selected from alcohol solvents, ester solvents, nitrile solvents, ketone solvents, polar solvents, polar aprotic solvents, hydrocarbon solvents, ether solvents or mixture thereof, and optionally heating the reaction mixture to a suitable temperature ranging from about 25° C. to about 100° C.

### Claim 25 (depends on 23)

The process for preparation as per claim 23, wherein the solvent is mixture of ethyl acetate and n-heptane.

### Claim 26 (depends on 23)

The process for preparation as per claim 23, wherein the solvent is mixture of n-heptane and methyl tertiary butyl ether (MTBE).

### Claim 27

A process for preparation of crystalline form-M5 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
a) dissolving compound of formula-1 and methyl paraben in a solvent,
b) optionally filtering the obtained solution, and
c) isolating crystalline form-M5 of compound of formula-1.

### Claim 28 (depends on 27)

The process for preparation as per claim 27, wherein the solvent is selected from alcohol solvents, ester solvents, nitrile solvents, ketone solvents, polar solvents, polar aprotic solvents, hydrocarbon solvents, ether solvents or mixture thereof, and optionally heating the reaction mixture to a suitable temperature ranging from about 25° C. to about 100° C.

### Claim 29 (depends on 27)

The process for preparation as per claim 27, wherein the solvent is ethyl acetate.

### Claim 30 (depends on 27)

The process for preparation as per claim 27, wherein the solvent is acetonitrile.

### Claim 31

A crystalline form-M6 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 6.

### Claim 32

A process for preparation of crystalline form-M6 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
a) suspending compound of formula-1 and methyl paraben in a solvent, and
b) isolating crystalline form-M6 of compound of formula-1.

### Claim 33 (depends on 32)

The process for preparation as per claim 32, wherein the solvent is selected from alcohol solvents, ester solvents, nitrile solvents, ketone solvents, polar solvents, polar aprotic solvents, hydrocarbon solvents, ether solvents or mixture thereof;

### Claim 34 (depends on 32)

The process for preparation as per claim 32, wherein the solvent is mixture of ethyl acetate and n-heptane.

### Claim 35 (depends on 32)

The process for preparation as per claim 32, wherein the solvent is mixture of n-heptane and methyl tertiary butyl ether.

### Claim 36

A pharmaceutical composition comprising crystalline polymorph of compound of formula-1 of any of preceding claims and at least one pharmaceutically acceptable excipient.

### Claim 37

A method of treating for the patients with Mental cell lymphoma or Chronic lymphocytic leukemia comprising administering to the said patient a therapeutically effective amount of crystalline polymorph of compound of formula-1 of any of preceding claims.
